Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Seedless Strains Could Dominate Future of Marijuana Industry

Cannabis may be colloquially known as weed, but the truth is that cultivating a batch of healthy and profitable cannabis plants requires plenty of care and attention to detail. A fickle plant in many ways, cannabis often gives cultivators a hard time, especially if those cultivators are commercial growers with large scale cultivations.

One major issue that plagues commercial growers and has the potential to reduce their yield is pollination. Cannabis is dioecious, which means it produces male and female flowers on separate plants. Once female plants are pollinated, the quantity and quality of their yield is reduced significantly.

As such, the cannabis industry has come to revere seedless varieties that do not produce seeds. A special strain dubbed cannabis sinsemilla, which is Spanish for “without seeds,” was created in the 1970s by separating female plants from their pollen-producing male counterparts.

Triploid cannabis strains are the next stage in the industry’s quest for seedless cannabis varieties. Normally, cannabis plants are diploid, meaning they have 10 pairs of chromosomes. Research in recent years has revealed that cannabis can also have four copies (tetraploid) and eight copies (octoploid). Scientists also managed to develop cannabis plants with triploid expression by crossing a diploid plant with a tetraploid.

With most of the market placing a higher value on seedless cannabis varieties, strains such as triploid cannabis are poised to become the industry standard as they have a significant advantage over seeded varieties. Although cannabis sinsemilla is seedless, it is still sensitive to pollen. If there are any males within your plants, they can pollinate the female and significantly reduce your yield.

Even if you manage to weed out every male, your female plants will still be sensitive to pollen from cross-pollination. Triploid varieties avoid this pitfall by being insensitive to pollen; in addition, they will not produce seeds even if they are pollinated, meaning growers don’t have to spend time and resources separating the males from the females or worrying about cross pollination.

By investing in triploid varieties rather than cannabis sinsemilla, growers can reduce the risk of cross-pollination by nearly 100%, allowing them to maximize their yields and scale up their production without having to deal with crop losses. Seedless strains that are not sensitive to pollination also provide an opportunity to cut down on labor costs because there will be no need to keep males and females separated.

Large-scale cannabis operations stand to benefit a great deal from seedless cannabis varieties. Companies such as Dark Heart Industries are already working to perfect triploid strains that are insensitive to pollination. The cannabis industry may soon be awash with triploid cannabis as growers take advantage of the numerous benefits they offer.

It could be interesting to see how those seedless cannabis varieties would perform when grown in the high-tech micro gardens made by Advanced Container Technologies Inc. (OTC: ACTX) and other such companies.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Researchers Find That THC Blood Tests Don’t Detect Impairment

New research has found additional evidence that THC levels detected in the breath or blood of marijuana users isn’t a dependable impairment indicator. The scientists discovered that THC levels in the breath and blood didn’t offer dependable evidence of how recently an individual had used marijuana.

For their study, the researchers recruited test subjects that were mostly individuals whom were daily marijuana users as test subjects. The researchers then determined the levels of THC in their breath and blood before and after each of them inhaled marijuana.

Before they inhaled marijuana, most of the participants had residual levels of THC of 5ng/ml or higher. This value exceeds the legal limit in a number of states. In their report, the researchers noted that THC at levels like this was still detectable, despite the absence of impairment. After each of the participants had inhaled the marijuana, the scientists observed an inverse relationship between performance impairment and levels of THC in the blood.

The researchers stated that their findings were consistent with other studies that have found that THC is detectable in an individual’s breath a number of days after it was last used. They explained that breath-based testing technologies for marijuana use relied solely on detecting THC’s presence, and they could result in test outcomes that were false positives. This is because THC’s presence in an individual’s breath was detectable outside the window of impairment.

These findings are consistent with the results of a separate study that was published last year in the “Neuroscience & Biobehavioral Review” journal. Scientists in this study conducted an analysis of research on concentrations of THC in the saliva and blood and driving performance.

Dr. Danielle McCartney, the lead author of this study, stated that higher concentrations of THC in the blood were only weakly linked to increased impairment in occasional users of marijuana, noting that no significant relationship was observed in regular users of marijuana. This suggested that concentrations of THC in oral fluid and blood were poor indicators of THC-induced impairment from marijuana consumption.

McCartney noted that the group’s findings showed that individuals who weren’t impaired could be identified mistakenly as marijuana intoxicated when the limits of THC are imposed by the law. The researchers noted that their findings called into question the reliance on levels of THC by law enforcement in America and the validity of random testing for THC in saliva.

The study’s findings were published in the “Scientific Reports” journal.

The entire marijuana industry, including entities such as American Cannabis Partners, can be expected to look forward to reliable technology that detects marijuana impairment and prevents users from being victimized for past cannabis use simply because metabolites are still detectable in their systems.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Grants DehydraTECH(TM) License to Ireland-Based AnodGen Bioceuticals

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the awarding of a five-year, non-exclusive DehydraTECH(TM) license from its wholly-owned subsidiary, Lexaria Pharmaceutical Corp., to AnodGen Bioceuticals of Ireland. According to the update, the awarded license is valid for the manufacturing and distribution of DehydraTECH-processed cannabinoid active pharmaceutical ingredient (“API”) powders within Europe including the U.K., Australia and New Zealand; including pharmaceutical and medical product applications for psychoactive cannabinoids and medical product applications for non-psychoactive cannabinoids. AnodGen, which has the right to manufacture and sell these API powders to third party companies for their own products designated by a national regulator as a medical product, drug, nutraceutical, pharmaceutical or biopharmaceutical, will pay royalty fees to Lexaria for all API powders sold that utilize the DehydraTECH technology. “This strategic alliance with Lexaria Bioscience Corp. underscores the focus of AnodGen to ‘Bring Science to Life,’ in addition to our research and APIs,” said Dr Slimane Aboulkacem, chairman and founding member of AnodGen Bioceuticals.

To view the full press release, visit https://cnw.fm/i8kzk

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

InvestorNewsBreaks – Home Bistro Inc. (HBIS) Engages Alab Group for Brand Strategy Expertise

Home Bistro (OTC: HBIS), a leading online meal delivery platform that offers celebrity chef-inspired, gourmet and lifestyle ready-made meals, today announced that it has retained public relations firm Alab Group, known for its work across hospitality, food and lifestyle initiatives, to assist in the development of new brand strategies. Under the collaboration, Alab will work with an initial focus on Home Bistro to oversee, develop and execute an overarching communication strategy with a secondary phase to support the Model Meals’ brand. “Our new relationship with Alab is extremely important to the company’s continued growth,” said Home Bistro’s Chief Marketing Officer Danika Brysha. “Given their expertise and proven abilities, over the next few months we expect to further strengthen our celebrity-chef focused brand presence, increase visibility for Home Bistro and Model Meals on a national level, and increase sales and new customer acquisition through a variety of public channels. This is an important next step in the evolution of the Home Bistro platform and Model Meals brand, and we are looking forward to the success of this meaningful partnership.”

To view the full press release, visit https://ibn.fm/obmWD

About Home Bistro Inc.

Home Bistro is a leading online platform that provides for the creation, production and distribution of direct-to-consumer, heat-to-eat, celebrity chef inspired gourmet meals, which currently include inspirations developed by “Iron Chef” Cat Cora, Ayesha Curry, “Hungry Fan” Chef Daina Falk, “Master Chef” Claudia Sandoval, “Top-Chef All-Star” Richard Blais, Celebrity Pastry and Dessert Chef Melanie Moss, and soon to launch celebrity chefs Roblé Ali and Priyanka Naik. Home Bistro’s Model Meals lifestyle brand is a Whole30 and Paleo approved, ready-to-eat, meal prep service, offering a weekly rotating menu that is prepared by professional chefs, using only the highest quality ingredients available, sourced responsibly and locally, and delivered in sustainable, eco-friendly packaging. For more information, visit www.HomeBistro.com.

NOTE TO INVESTORS: The latest news and updates relating to HBIS are available in the company’s newsroom at https://ibn.fm/HBIS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Flora Growth Corp. (NASDAQ: FLGC) Adding to Cannabis Product Line, Research

  • Flora Growth is building on its cannabis brand globalization efforts with two partnerships that expand its product portfolio and its research efforts in the United States and United Kingdom
  • Flora’s partnership with former NFL athlete Ricky Williams has delivered its first product — a cannabis one-hitter accessory designed to provide a unique experience emblematic of Williams’ active lifestyle brand
  • The company’s acquisition of the Masaya CBD brand developed by a cell biologist on Flora’s board of directors gives the company a formulation suitable for its current clinical trial efforts in the United Kingdom, and a well-received brand designed to help seizure patients
  • Flora’s cultivation operations are centered at its Colombia facility, and recent regulatory changes there have made it easier for Flora to supply its brands in the United States and elsewhere

On the heels of a year in which global cannabis market brand-builder Flora Growth (NASDAQ: FLGC) saw rapid expansion of its cultivation, manufacturing and distribution operations that support the company’s business divisions for cosmetics, hemp textiles and food and beverage products, Flora is increasing its offerings by bringing a promising  CBD brand into its fold and introducing a new product for quality cannabis experiences. 

The acquisition of cell biologist Dr. Annabelle Manalo-Morgan’s Masaya brand gives Flora Growth its first offering under its Flora Life Sciences division as well as a patent-pending formulation for use in Flora’s current clinical trials with the University of Manchester in the United Kingdom (https://cnw.fm/05Tev).

The launch of the global clinical trials was announced in October, heralding an effort to study the effects of Flora’s cannabis on fibromyalgia and chronic pain patients (https://cnw.fm/Fu6lQ). Manalo-Morgan developed the formulation for Masaya after her son was born with a condition that led him to suffer from as many as 200 seizures per day. 

Manalo-Morgan’s son initially underwent surgery that removed nearly 40 percent of his brain, but Manalo-Morgan’s discovery of CBD’s medicinal potential and development of Masaya’s formulation provided her a non-surgical path for ensuring her son’s well-being. 

“He has no developmental deficits. If you saw him, you would never know there was a thing wrong with him. He is not autistic, delayed, nothing. He is a normal 5-year-old boy,” Manalo-Morgan told a news reporter as her son prepared to enter kindergarten last year (https://cnw.fm/DjMth). “If I didn’t do this, my son would most likely be tied to a wheelchair, wouldn’t speak, would still be eating out of a tube. But luckily his mom is a scientist.”

Masaya has been used by thousands of consumers since its development with positive testimonials. 

“Amplifying Dr. Annabelle and her son’s beautiful story and improving the well-being of people around the world is our aim,” Flora Chairman and CEO Luis Merchan stated in the company’s news release. “This acquisition allows us to deliver on our promise to invest in safe, thorough, cutting-edge scientific research that can bring meaningful change via an efficacious and accessible product offering for people worldwide.”

On May 18, Flora also announced the development of a custom accessory for cannabis use in collaboration with cannabis lifestyle brand Highsman, which was founded by former NFL running back Ricky Williams. 

The patent-pending Highsman Helix one-hitter accessory is the first product introduced under the partnership between Highsman and Flora’s cannabis accessories brand Vessel (https://cnw.fm/ipHTH). It is crafted in non-toxic brass and uniquely designed to offer “the perfect combination of filtering and cooling.” 

Vessel’s other luxury accessories include a high-end line of vape pen batteries and dry-herb accessories, while Highsman also markets apparel and other accessories designed to appeal to people with active lifestyles, inspired by Williams’ success. 

For more information, visit the company’s website at www.FloraGrowth.com.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — States Grapple with Setting Regulations for Hemp-Derived Intoxicating Products

America’s hemp industry has been plagued by one major issue since the 2018 Farm Bill legalized industrial hemp: federal inaction. While the legislation allowed the cultivation and sale of industrial hemp under state programs, lawmakers did not create a comprehensive regulatory structure for hemp or hemp-derived products.

The result is a sector that has been referred to as a “wild west” where businesses barely have any rules governing how they operate and which products they can put out into the market. One of the core provisions for legalizing industrial hemp was that it had to contain less than 0.3% delta-9 THC, which is the main intoxicating agent in marijuana.

However, lack of federal action has led to the proliferation of cannabinoids other than delta-9 THC with the ability to intoxicate users. States are now grappling with how to deal with psychoactive cannabinoids such as delta-8 THC, which aren’t explicitly covered in the Farm Bill’s language.

In Tennessee, for instance, the market has been flooded by unregulated products dubbed “frankenweed” due to claims of them being created in laboratories. Lawmakers were faced with the choice of either banning delta-8 THC and other psychoactive hemp-derived cannabinoids or setting safety standards for the market.

Nashville lawmakers were unable to make a decision early enough, leaving the state inundated with intoxicating and possibly dangerous THC products with no safety oversight or age requirements for purchasing. Hemp Alliance of Tennessee president Frederick Cawthon calls the entire ordeal a “roller-coaster ride.”

Federal ambiguity regarding hemp-derived products is to blame for this regulatory roller coaster. The greatest beneficiary of this ambiguity has been CBD, a hemp extract said to have medical applications. As long as the hemp they were derived from met the less than 0.3% delta-9 THC threshold, cannabinoids such as CBD and delta-8 THC are considered legal.

This ambiguity also means that hemp operators may act contrary to some food and drug laws despite following hemp laws. The U.S. Food and Drug Administration (FDA), which has been charged with creating concise hemp rules, has barely made a move to regulate the multitude of hemp extracts that are steadily emerging.

Denver-based lawyer Shawn Hauser says the FDA’s inaction has forced states to step up and craft their own rules for dealing with hemp-extracted intoxicants. During a recent webinar meant to help unravel the resulting complex patchwork of hemp regulations, Hauser said that states still run into problems when they try to set limits on synthetic, or‘intoxicating, hemp products as federal law has no definition for these terms.

Colorado, Kentucky, Virginia and at least 10 other states have considered proposals designed to regulate the sale of hemp derivatives this year while the Minnesota and Maryland legislatures have already passed bills to place limits on the sale of hemp intoxicants.

The lack of federal regulations governing commerce in hemp derivatives poses a big challenge to industry actors, such as Flora Growth Corp. (NASDAQ: FLGC), that would like to establish their footprint across different jurisdictions. This is because it is hard to tweak different products in order to adhere to the patchwork of rules (where they exist) in different states.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Maryland Official Wants DOJ to Investigate Possible Flaws in FBI Cannabis Arrest Data

An official in Maryland is asking that the Department of Justice formally investigate the system of reporting used by the FBI for local and state cannabis arrests. The key issue is the confusion among agencies of law enforcement on the issuance of citations for the possession of marijuana under decriminalization laws in the state and whether they should be reported as arrests to the FBI.

This confusion has caused inconsistency in the data that is released annually, calling into question the data’s use as a tool to inform policymaking on cannabis. The reporting system, which is known as the Uniform Crime Reporting program, is depended on by researchers, legislators and media to examine and understand law enforcement trends, with more than 18,000 jurisdictions in the country reporting to the agency on why and how many types of arrests are made annually using it.

Maryland official Eric Sterling believes that the arrest data on marijuana that was reported through the program may be embellished after a state police department recently revealed in an interview that they categorized simple civil violations for the possession of marijuana as arrests.

The state of Maryland decriminalized cannabis in 2014 and made the possession of 10 grams of the herb a civil violation punishable by a fine without the threat of jail time or even arrest.

Despite the lack of arrest for such a violation, state police in Maryland report fine issuance as arrests. This is because the National Incident-Based Reporting System manual instructs that violation of laws that prohibit the use, distribution or production of some controlled substances be reported but offers no distinction between criminal arrests and civil violations.

This apparent inconsistency is what prompted Sterling to demand an investigation be done by the Office of the Inspector General. Sterling explained that miscounted arrests undermined the value of cannabis decriminalization as a cost saver for law enforcement, noting that the arrest data may influence federal funding for local and state police departments under several programs.

The issue may have considerable implications for observers and policymakers evaluating the impact of decriminalization policies. An analysis has shown that this interpretation hasn’t been adopted in all departments, with some reporting substantially less cannabis arrests postdecriminalization.

It is not clear how many police agencies in the country classify citations as arrests. However, cities such as Baltimore are using a different reporting style, with far fewer marijuana arrests being reported since its state enacted decriminalization laws.

The response to this appeal is likely to be of interest to the entire marijuana industry, including entities such as Cannabis Strategic Ventures Inc. (OTC: NUGS) because FBI data on different arrests plays a crucial role in informing what stance policy makers at the highest level take.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Closes $5M Direct, Private Placement Offerings

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has closed on its registered direct offering and concurrent private placement with a single healthcare-focused institutional investor; the offerings were priced at-the-market under Nasdaq rules. According to the announcement, for the registered direct offering, INM issued 4,079,256 common shares at a purchase price of $0.858 per share (or prefunded warrant in lieu thereof). For the concurrent private placement, InMed issued and sold to the investor 1,748,250 common shares (or prefunded warrant in lieu thereto); those shares were offered at the same purchase price as those associated with the registered direct offering. InMed noted that it also issued unregistered preferred investment options to the investor; those investment options allowed for the purchase of up to 5,827,506 common shares. The announcement also outlined amendments to existing warrants that had been previously issued to the same investor. According to the announcement, the company could see gross proceeds from both offerings reach an estimated $5 million. InMed anticipates using the net proceeds from the offerings to continue pipeline development and advance commercial activities as well for general working capital purposes.

To view the full press release, visit https://cnw.fm/91OXR

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary BayMedica LLC, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and is dedicated to delivering new treatment alternatives to patients who may benefit from cannabinoid-based pharmaceutical drugs. For more information, please visit www.InMedPharma.com.  

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Regulators in New York Urge Tiktok to Desist from Banning Educative Cannabis Content

Cannabis regulators in New York are asking that TikTok put an end to the ban placed on advertising anything involving the word cannabis, as they promote public education on New York’s move to legalize the herb. The state’s Office of Cannabis Management sent a letter to the social media app’s executives urging them to amend the platform’s policy on advertisement for government entities so they could talk about cannabis in a public health and safety context freely.

Chris Alexander, the office’s executive director, also revealed that the office had launched a campaign to inform residents in the state about how they could safely use marijuana, where they could legally use it and who could purchase it.

Alexander stated that the office was airing advertisements from this campaign on billboards in the state, on broadcast television and on a number of social media platforms. He noted, however, that the office was not allowed to air the advertisements on TikTok. He explained that the cannabis management office hopes that it could be permitted to run public health campaigns on cannabis, which are similar to the ads run by the state’s Department of Health on this particular platform. He added that TikTok was a valuable asset when it came to advertising because the application has more than a billion users.

Over 70% of TikTok users are aged between 18 and 34, which may assist regulators in straightening out any misinformation on who is allowed to purchase or possess cannabis when retailers launch their businesses later in the year. Currently, individuals aged 21 and above will be allowed to use, possess and purchase marijuana under the state’s legal adult-use market.

Allowing cannabis regulators to run ads on the platform would offer information to underage individuals on the effects of cannabis use at a young age while also delivering the message that it’s both illegal and unsafe to drive while impaired by marijuana.

The relationship between cannabis regulators, influencers and businesses and social media companies has been inconsistent and complicated amid the movement to legalize the herb. For instance, advocacy groups, state-legal marijuana businesses and government entities such as the California Bureau of Cannabis Control have accused Facebook of shadow banning them, which prevents their profile pages from coming up during a search.

This same issue has also been highlighted on Instagram, which is owned by Facebook, with some individuals revealing that their accounts were deleted on the application over cannabis-related content.

The continued ban of cannabis advertising by these platforms in state-legal markets denies duly licensed ancillary companies such as Advanced Container Technologies Inc. (OTC: ACTX) from accessing a large pool of their potential clients who are active on those social media platforms.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Study Says California Cannabis Retailers Fully Compliant in Checking IDs

A new study coming out of California has revealed that marijuana retailers in the state are doing a bang-up job at keeping underage people away from their merchandise. One of the major arguments against legalizing cannabis has been that it would increase youth access to the controversial drug and lead to an explosion of drug abuse and criminal activity.

To see whether or not California’s cannabis industry was compliant with state ID requirements, researchers sent 50 fresh-faced people to random cannabis dispensaries across the state. Each of the marijuana shops asked for an ID before admitting the decoys.

The study’s authors said that while the 100% compliance was somewhat surprising, it is in line with what has been seen in Colorado and Washington State. This compliance is most likely due to the penalties cannabis retailers face if they sell their products to underage people.

For starters, any Californian who provides marijuana to an underage individual faces a maximum fine of $500 and up to six months in jail for a first offense. Furthermore, the state allows police officers to test compliance to ID requirements using minors as decoys. Retailers who don’t comply can lose their retail license and face other penalties.

Published in the “Journal of Safety Research,” study findings says that since underage individuals don’t appear to be purchasing marijuana from legal outlets, it is likely they are getting it from other sources. This includes older siblings and friends, asking adults to obtain the drug on their behalf, or at parties where marijuana is being used and shared among the partygoers.

Although study authors acknowledged that their study provides evidence of policy compliance by cannabis retailers, they encouraged enforcement agencies and future studies to investigate the use of fake IDs at legal retailers by minors, and whether or not they were obtaining cannabis from social sources or illicit dispensaries.

This study is significant in two ways. First, it shows that current marijuana policies are effective at preventing youth access and second, that a legal, regulated marijuana market for adults is a much better alternative to total prohibition. It is consistent with results from several previous studies and reports.

One recent report from the Coalition for Cannabis Policy Education and Regulation (CPEAR) highlighted studies that proved that legalization did not lead to increased youth marijuana use rates.

One federally funded study also showed that 2021 saw a significant reduction in youth cannabis use while the National Survey on Drug Use and Health (NSDUH) revealed that cannabis use among the youth dropped in 2020.

Such research findings provide more vindication for the entire cannabis industry, including companies such as American Cannabis Partners, regarding the ability of legalization to curb underage marijuana access or use.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.